# Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Source: https://onco.cc/trials/nct05024214/  
OnCo record `nct05024214` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenvatinib, Envafolimab, Sunitinib in non-small-cell lung cancer and small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.

## Summary

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05024214 by 3D Medicines (Sichuan) Co., Ltd., with 170 participants planned, started 2021-11-15 and due to reach its primary completion in 2026-12. Interventions recorded: Lenvatinib + Envafolimab, Sunitinib. Conditions listed: Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05024214
- Phase: 1/2
- Setting: Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT05024214: https://clinicaltrials.gov/study/NCT05024214

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Envafolimab](https://onco.cc/drugs/envafolimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05024214.json